How to Buy Viridian Therapeutics Stock
Viridian Therapeutics Inc
Viridian Therapeutics, Inc. , a biotechnology company, develops treatments for patients suffering from serious diseases.
Viridian Therapeutics stock last closed at $13.76, up 4.8% from the previous day, and has decreased 3.78% in one year. It has overperformed other stocks in the Biotechnology industry by 0.73 percentage points. Viridian Therapeutics stock is currently +38.99% from its 52-week low of $9.90, and -49.41% from its 52-week high of $27.20.
As of Apr 22, 2025, there are 81.48M VRDN shares outstanding. The market cap of VRDN is $1.12B. In the last 24 hours, 984,098 VRDN shares were traded.
How to Buy Viridian Therapeutics Stock
Not sure how to invest in Viridian Therapeutics stock? Here's how.
- Decide where to buy Viridian Therapeutics stock: You need to decide on an online brokerage, but don't worry - we've tested dozens of online stock brokerages and apps to help you figure out where to buy Viridian Therapeutics stock.
- Open a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've found.
- Deposit money your investment account: Pick your method of payment and add your information.
- Evaluate Viridian Therapeutics stock: The Viridian Therapeutics ticker symbol is VRDN. Is Viridian Therapeutics stock a good investment? Should you buy shares of VRDN? How do VRDN's underlying business fundamentals look? Do top analysts think Viridian Therapeutics is a good buy? Why has VRDN's stock price moved recently? (Hint: Our stock research website can help you evaluate if VRDN is a good stock to buy).
- Execute your VRDN buy order: Decide if you will purchase VRDN shares at the current market price or use a limit order to buy VRDN stock at a given price.
- Get notifications regarding your VRDN position: Create a watchlist to keep tabs on your investment in Viridian Therapeutics stock.
Step 1: Decide where to buy Viridian Therapeutics stock
You will need a brokerage account to access the NASDAQ market and buy VRDN shares.
Our preferred brokerage: eToro
We believe that eToro is the best stock brokerage. eToro gives you:
- You can invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
- Access to world markets: From Tech to Industrials, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's top exchanges.
- Social investing: eToro boasts a community of more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your purchase of shares by opening an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Open a brokerage account
Now that you've chosen the best brokerage, it's time to fill out some personal details so you can buy VRDN stock today.
How to Start a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal data to create a new trading account.
- Send your information by clicking the "Create Account" button. Get started with eToro today
Step 3: Deposit money your investment account
Now that you have finished signing up on the best stock app for beginners, your next step is to transfer the money for your investment:
Check out the tutorial below to see the process of transferring funds into your brokerage account.
Step 4: Evaluate Viridian Therapeutics stock
After you have selected the best place to buy Viridian Therapeutics stock, it's very important to research their stock before you invest, so you actually understand the risk and opportunity.
Viridian Therapeutics quick stats
VRDN Fundamentals
WallStreetZen was built to help average investors perform better fundamental analysis.
You can view all of the due diligence checks on VRDN's stock page.
Is VRDN stock undervalued or overvalued?
Analysts use many financial metrics, analyses, models, and charts to gauge VRDN's true value.
Using relative valuations methods:
- VRDN may be undervalued based on its P/B ratio of 1.67x, relative to Biotechnology industry P/B ratio of 4.16x
You can do additional valuation research on VRDN's stock here.
VRDN Financial Health Summary
Pros:
- VRDN has $717.58M in cash and short term investments. This is sufficient to cover its annual cash burn of $232.83M.
- VRDN has a low debt to equity ratio of 0.11.
- There are more short-term assets than short-term liabilities on the VRDN balance sheet.
- There are more short-term assets than long-term liabilities on the VRDN balance sheet.
- VRDN has cash burn of 232830000. It has enough cash and short-term investments to cover this for at least one year.
- Total VRDN debt is lower than 5 years ago, relative to shareholder equity.
Cons:
- VRDN profit margin has gone down from -75,711.5% to -89,387.1% in the past year.
Is Viridian Therapeutics stock a Buy, Hold, or Sell, according to analysts?
Out of 4 sell side analysts who monitor VRDN, the consensus analyst rating on Viridian Therapeutics is a Buy
It's important to note that analyst forecasts are not stock recommendations, nor are they financial advice.
You can dive deeper into what analysts are saying on the Viridian Therapeutics stock forecast page.
VRDN Technical Indicators
How is VRDN performing as a company?
Last year, VRDN revenue was $302.00k. During the past 5 year, VRDN's revenue has increased by -41.64% per year. This was slower than the Biotechnology industry average of 44.4%.
You can analyze VRDN's earnings and revenue performance here.
Are VRDN insiders buying or selling the stock?
In the last 12 months, executives and large shareholders at VRDN have bought more shares than they have sold.
Thomas W. Beetham, Chief Operating Officer of VRDN, was the latest VRDN insider to buy. They bought $117,050.00 worth of VRDN stock on Sep 27, 2024.
Get more info about who owns VRDN shares here.
Does VRDN provide a stable income stream?
No, Viridian Therapeutics doesn't provide an income stream by paying out dividends.
What others are saying about VRDN
One of the primary reasons eToro is our favorite brokerage is because of its social trading community.
Click below to see what other traders have to say.
Step 5: Execute your VRDN buy order
You have two primary types of orders:
- Market order: A market order is an order to buy or sell a stock at the best price on the market.
Market orders are generally the easiest way to buy. - Limit order: A limit order enables you to buy or sell a security at a specific price (or better).
If you want to be certain you're buying or selling at a particular price limit, use a limit order.
Hit the Open button and eToro will execute your order.
If you require more assistance investing in stocks on eToro, click the how to video below:
Step 6: Get notifications regarding your VRDN position
Now that you own some VRDN shares, you'll want to stay up-to-date on your shares.
Make a watchlist to track the latest developments regarding your VRDN stock.
VRDN Feed
How to Buy Stock in Viridian Therapeutics
To summarize, here are the 6 steps you need to take to buy Viridian Therapeutics stock right now:
- Decide where to buy Viridian Therapeutics stock
- Open a brokerage account
- Deposit money your investment account
- Evaluate Viridian Therapeutics stock
- Execute your VRDN buy order
- Get notifications regarding your VRDN position
If you are looking for a online brokerage, eToro is our favorite option.
Get Started with eToro TodayIf you want to get the latest scoop on your new investment in Viridian Therapeutics, click below.
More Articles You May Like
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.